CompletedNot Applicable

Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine

Switzerland835 participantsStarted 2021-12-10

Plain-language summary

This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.

Who can participate

Age range16 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * individuals working at the University Hospital Basel, Switzerland * informed consent available * 16-65 years old Exclusion Criteria: * Refusal to participate at the study * Cardiac events or cardiac surgery within 30 days prior to study (as these could result in prolonged hs-cTnT elevations and interfere with the diagnosis of myocarditis

What they're measuring

Incidence of myocarditis after mRNA COVID-19 mRNA booster vaccine

Timeframe: Assessment at day 3 (48- 96h) post-vaccination

Trial details

NCT IDNCT05438472

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-04-20

View on ClinicalTrials.gov More Myocarditis trials